No Data
Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20
Maxim Group analyst Naz Rahman maintains $Clene(CLNN.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 34.3% and a total
Clene's CNM-Au8 Shows Promise in ALS Treatment Despite Trial Setbacks: A Strong Buy Recommendation
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31
H.C. Wainwright analyst Joseph Pantginis maintains $Clene(CLNN.US)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 37.1% and a
Buy Rating Justified by Regulatory Progress and Positive ALS Treatment Data for Clene's CNM-Au8